Schedule 13D ownership disclosure
Gyre Therapeutics Inc
Security class unavailable · CUSIP: 403783103
Event date: 2023-10-30
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 73,313,885
- Percent of class
- 85.3600%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001140361-23-050866
- Form type
- SC 13D
- Filer
- GNI Group Ltd.
- CIK
- CIK 1958461
- Filed
- Nov 01, 2023
- Reporting period
- Oct 30, 2023
- Description
- Schedule 13D beneficial ownership